Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Jones

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
The Pediatric Infectious Disease Journal|November 16, 2016
Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak StrainsShannon L Harris, Robert G K Donald, Julio Cesar Hawkins, et al.
Human Vaccines & Immunotherapeutics|December 15, 2016
Meningococcal serogroup B vaccines: Estimating breadth of coverageRobert G K Donald, Julio Cesar Hawkins, Li Hao, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 20, 2003
Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance inductionAndrew B Adams, Nozomu Shirasugi, Thomas R Jones, et al.
The Pediatric Infectious Disease Journal|March 15, 2016
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US AdolescentsDerek Muse, Shane Christensen, Prakash Bhuyan, et al.
Vaccine|December 29, 2015
Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workersDavid M Reiner, Prakash Bhuyan, Joseph J Eiden, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N'-arylthiourea inhibitors of CMVJonathan D Bloom, Russell G Dushin, Kevin J Curran, et al.
Vaccine|January 29, 2013
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adultsHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
Journal of Virology|January 29, 2003
Identification of small molecule compounds that selectively inhibit varicella-zoster virus replicationRobert J Visalli, Jeanette Fairhurst, Shamala Srinivas, et al.
The Pediatric Infectious Disease Journal|June 22, 2012
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trialHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
The Pediatric Infectious Disease Journal|February 3, 2016
Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus VaccineShelly Senders, Prakash Bhuyan, Qin Jiang, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
The Pediatric Infectious Disease Journal|November 16, 2016
Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak StrainsShannon L Harris, Robert G K Donald, Julio Cesar Hawkins, et al.
Human Vaccines & Immunotherapeutics|December 15, 2016
Meningococcal serogroup B vaccines: Estimating breadth of coverageRobert G K Donald, Julio Cesar Hawkins, Li Hao, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 20, 2003
Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance inductionAndrew B Adams, Nozomu Shirasugi, Thomas R Jones, et al.
The Pediatric Infectious Disease Journal|March 15, 2016
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US AdolescentsDerek Muse, Shane Christensen, Prakash Bhuyan, et al.
Vaccine|December 29, 2015
Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workersDavid M Reiner, Prakash Bhuyan, Joseph J Eiden, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N'-arylthiourea inhibitors of CMVJonathan D Bloom, Russell G Dushin, Kevin J Curran, et al.
Vaccine|January 29, 2013
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adultsHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
Journal of Virology|January 29, 2003
Identification of small molecule compounds that selectively inhibit varicella-zoster virus replicationRobert J Visalli, Jeanette Fairhurst, Shamala Srinivas, et al.
The Pediatric Infectious Disease Journal|June 22, 2012
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trialHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
The Pediatric Infectious Disease Journal|February 3, 2016
Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus VaccineShelly Senders, Prakash Bhuyan, Qin Jiang, et al.
Pageof 7